文献速递慢性肾脏病肾移植血液净化与透析

CKD与肾移植中的矿物质骨病:争议、差距与前进方向

Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward.
PubMed 文献 · Kidney Int Rep · 2026-06-16

本文综述CKD相关矿物质骨病(CKD-MBD)的病理生理进展,提出两个重叠临床综合征:CKD相关骨质疏松和CKD相关心血管病。CKD患者骨折率超同龄对照>4倍,透析患者风险增加≤8倍;现有诊断工具不足,治疗存在虚无主义,需个性化风险分层和临床试验。

要点

  • CKD-MBD概念更新为CKD相关骨质疏松和CKD相关心血管病两个重叠综合征。
  • CKD患者骨折率超同龄对照>4倍,透析患者风险增加≤8倍。
  • 骨活检为金标准但常规不实用,DXA不能区分肾性骨营养不良类型。

核心结论

  • CKD-MBD病理生理远超单纯矿物质失衡,涉及两个重叠临床综合征。
  • CKD患者骨折风险显著增高,但多数高危患者未接受骨靶向治疗。
  • 需放弃治疗虚无主义,推行个性化风险分层并在既往排除人群中开展试验。

研究设计与样本

  • 综述,检索范围未在原文摘要中报告。

主要发现

  • CKD患者骨折率超年龄匹配对照>4倍,透析患者风险增加≤8倍。
  • FGF-23早期升高、磷酸盐潴留、维生素D活化减少、继发性甲旁亢和尿毒症毒素积累共同 disrupt 骨细胞功能。
  • 透析人群蛋白质能量消耗影响多数患者,肾移植后糖皮质激素、免疫抑制剂和抗凝治疗加剧骨病。
  • TBS在预测继发性骨质疏松人群骨折风险上略优于传统密度测定,但需长期随访大型临床试验。

关键数值与推荐

  • 骨活检为诊断金标准但常规实践不实用。
  • DXA不能提供肾性骨营养不良类型信息,严重血管钙化时受限。
  • FGF-23、a-Klotho和骨转换参数等生物标志物效用仍有争议。

临床怎么用

  • 应放弃治疗虚无主义,对高危CKD患者考虑骨靶向治疗。
  • 需改进诊断和预测工具以识别高危患者。
  • 治疗选择包括甲状旁腺切除术、双膦酸盐、地舒单抗、特立帕肽、罗莫索单抗;burosumab仍在研究中。

局限性

  • 骨活检常规不实用,DXA在严重血管钙化时受限。
  • 新型生物标志物效用未定,TBS需大型长期临床试验验证。
  • burosumab在该人群无已发表临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The pathophysiology of chronic kidney disease (CKD)-related mineral and bone disorder (CKD-MBD) extends far beyond simple mineral imbalances. Evolving from the traditional understanding of secondary hyperparathyroidism, the conceptual framework has recently been updated to recognize 2 distinct but overlapping clinical syndromes: CKD-associated osteoporosis, which encompasses the significantly increased fracture risk and microarchitectural deterioration in this population; and CKD-associated cardiovascular disease, which accounts for vascular and structural cardiac abnormalities, including medial vascular calcification. Unlike traditional osteoporosis, the 2 clinical syndromes emerge from intricate interactions between declining kidney function and dysregulated mineral metabolism. The early rise in fibroblast growth factor-23 (FGF-23) levels; progressive phosphate retention; diminished vitamin D activation; secondary hyperparathyroidism; and uremic toxin accumulation, particularly uric acid and indoxyl sulfate, orchestrate profound disruptions in osteocyte, osteoblast, and osteoclast function. The complex interaction amplifies in the dialysis population, where protein-energy wasting affects most patients; and intensifies following kidney transplantation because of glucocorticoid, immunosuppressive, and anticoagulant treatments. Consequently, fracture rates in patients with CKD exceed those of age-matched controls by >4-fold, with patients on dialysis therapy facing a ≤ 8-fold increased risk. Available diagnostic and predictive tools need to be improved to adequately identify at-risk patients. The usefulness of additional, more recent biomarkers such as FGF-23, a-Klotho, and various bone turnover parameters remains a matter of debate. Bone biopsy, considered as the diagnostic gold-standard, remains impractical in routine practice. Dual-energy X-ray absorptiometry (DXA) cannot provide information on the type of renal osteodystrophy. Moreover, it demonstrates limitations in the presence of severe vascular calcifications. Trabecular bone scores (TBS) emerge as potential progress in noninvasive bone imaging, showing modest superiority over traditional densitometry in predicting fracture risks among secondary osteoporosis populations, yet large clinical trials with long-term follow-up are required. Therapeutic management spans from parathyroidectomy to pharmacological interventions with bisphosphonates, denosumab, teriparatide, romosozumab, whereas agents such as burosumab remain investigational, with no published clinical trials in this population. However, therapeutic nihilism persists, with most high-risk patients not receiving bone-targeted therapy despite accumulating safety data. Transforming care demands abandoning therapeutic nihilism, embracing personalized risk stratification, and conducting trials in populations historically excluded from bone health research.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kanbay M, Aktas O, Copur S, et al. Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward. Kidney Int Rep. 2026. PMID: 42438722. doi:10.1016/j.ekir.2026.106662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。